×
About 6,633 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  2,224 results

The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gra...
https://doi.org/10.1016/j.nmd.2022.09.002
Neuromuscular Disorders : NMD; Remijn-Nelissen L, Verschuuren JJGM et. al.

Oct 3rd, 2022 - Pyridostigmine is the most commonly used drug in the symptomatic treatment of myasthenia gravis (MG); however, research into its effectiveness and side effects is scarce. The aim of this study was to assess the effectiveness, prevalence of side ef...

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04650854

Sep 30th, 2022 - The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).

Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis.
https://doi.org/10.1002/jcsm.13089
Journal of Cachexia, Sarcopenia and Muscle; Keene KR, Kan HE et. al.

Sep 30th, 2022 - Ophthalmoparesis and ptosis can be caused by a wide range of rare or more prevalent diseases, several of which can be successfully treated. In this review, we provide clues to aid in the diagnosis of these diseases, based on the clinical symptoms,...

Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19:...
https://doi.org/10.1016/j.clineuro.2022.107441
Clinical Neurology and Neurosurgery; Karimi N, Fatehi F et. al.

Sep 30th, 2022 - Myasthenia Gravis (MG) is an autoimmune disorder that can exacerbate for various reasons including infections. In this study, we describe clinical symptoms, outcomes, and management of MG patients affected by COVID-19 infection. This observational...

Familial autoimmunity in patients with idiopathic inflammatory myopathies.
https://doi.org/10.1111/joim.13573
Journal of Internal Medicine; Che WI, Westerlind H et. al.

Sep 28th, 2022 - Familial associations can be indicators of shared genetic susceptibility between two diseases. Previous data on familial autoimmunity in patients with idiopathic inflammatory myopathies (IIM) are scarce and inconsistent. To investigate which autoi...

see more →

Guidelines  4 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 5th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 10th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critical...
https://doi.org/10.1097/CCM.0000000000002027
Critical Care Medicine; Murray MJ, DeBlock H et. al.

Oct 19th, 2016 - To update the 2002 version of "Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient." A Task Force comprising 17 members of the Society of Critical Medicine with particular expertise in the use of n...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jul 1st, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

see more →

Drugs  67 results see all →

Clinicaltrials.gov  161 results

A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04650854

Sep 30th, 2022 - The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05403541

Sep 28th, 2022 - The purpose of this 3-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 3...

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT04980495

Sep 27th, 2022 - The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG). Study details include: T...

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
https://clinicaltrials.gov/ct2/show/NCT05556096

Sep 27th, 2022 - The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Convalescent Antibodies Infusion in COVID 19 Patients
https://clinicaltrials.gov/ct2/show/NCT04418531

Sep 23rd, 2022 - The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. Convalescent plasma or immunoglobulins have been used as a last resort to improve the su...

see more →

News  183 results

FDA Drug Approvals, Internal Medicine — 2022 Midyear Review
https://www.medscape.com/viewarticle/978844

Aug 24th, 2022 - Neurology Ztalmy (ganaxolone) Ganaxolone is a GABAA receptor–positive modulator. It binds specifically to GABAA receptors to enhance their inhibitory effects. It is indicated for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) defi...

FDA Drug Approvals, Neurology — 2022 Midyear Review
https://www.medscape.com/viewarticle/978845

Aug 24th, 2022 - Ztalmy (ganaxolone) Ganaxolone is a GABAA receptor–positive modulator. It binds specifically to GABAA receptors to enhance their inhibitory effects. It is indicated for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency dis...

FDA Drug Approvals, Family Medicine — 2022 Midyear Review
https://www.medscape.com/viewarticle/979456

Aug 24th, 2022 - Neurology Ztalmy (ganaxolone) Ganaxolone is a GABAA receptor–positive modulator. It binds specifically to GABAA receptors to enhance their inhibitory effects. It is indicated for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) defi...

FDA Drug Approvals — 2022 Midyear Review
https://www.medscape.com/viewarticle/979457

Aug 24th, 2022 - Neurology Ztalmy (ganaxolone) Ganaxolone is a GABAA receptor–positive modulator. It binds specifically to GABAA receptors to enhance their inhibitory effects. It is indicated for seizures associated with cyclin-dependent kinase-like 5 (CDKL5) defi...

Generalized Myasthenia Gravis Drug Receives EU Approval
https://www.medscape.com/viewarticle/979167

Aug 12th, 2022 - The European Commission has granted market authorization for efgartigimod (Vyvgart, argenx) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who test positive for anti–acetylcholine receptor (AChR) antibody. The...

see more →

Patient Education  14 results see all →